Month: August 2022

Correction: Gofore Plc’s Half-year Report for January-June 2022: Strategy execution continues to bring great results – net sales +40% and adjusted EBITA +54%

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Gofore Plc Half-year Report 15 August, 2022 AT 11.45 A.M. EET Inside information Correction: Gofore Plc’s Half-year Report for January-June 2022: Strategy execution continues to bring great results – net sales +40% and adjusted EBITA +54% The company corrects the Half-year Report 2022 on page 41; Corporate Acquisitions: the acquisition cost calculation was missing the section “Contingent consideration at the acquisition date” and this has now been added onto the attached report. In addition, the Finnish language version was missing the “Earnings per share” information in the “Statement of Profit and Loss and Other Comprehensive Income”. January-June 2022Net sales grew by 40% to EUR 72.5 (51.7) million. Organic net sales growth accounted for well over half of total growth (25%). Adjusted EBITA grew by 54% to EUR 10.7 (6.9) million. Adjusted...

Niu Technologies Announces Second Quarter 2022 Financial Results

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

— Second Quarter Total Volume of e-scooter sales down 17.4% year over year — Second Quarter Revenues of RMB 827.6 million, down 12.4% year over year — Second Quarter Net income of RMB 14.4 million, compared with net income of RMB 91.8 million in the same period of last year BEIJING, Aug. 15, 2022 (GLOBE NEWSWIRE) — Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsRevenues were RMB 827.6 million, a decrease of 12.4% year over year Gross margin was 20.3%, compared with 22.7% in the second quarter of last year Net income was RMB 14.4 million, compared with net income of RMB 91.8 million in the second quarter of last year Adjusted...

Interim Report for the period 1 January – 31 June 2022 – Progress in attendance and revenue leads to increased expectation

Written by Customer Service on August 15, 2022. Posted in Public Companies.

The Supervisory Board of Tivoli A/S has adopted the Interim Report for the period 1 January – 30 June 2022. Results for the period 1 January – 30 June 2022 in outline:A revenue of DKK 387.9 million compared to DKK 153.5 million last year (+ 153%). An EBITDA of DKK 5.1 million compared to DKK -55.4 million last year. EBITDA is DKK 60.5 million better than last year. A loss before tax of DKK -55.8 million compared to DKK -121.6 million last year. Loss before tax is DKK 65.8 million better than last year. An attendance figure of 1,196,000 attendants compared to 457,000 last year (+162%).”We are experiencing a really good summer season, where the guests make great use of our many rides, dining options and enjoy the cultural diversity of Tivoli and the Gardens. This has meant a significantly higher level of activity in the first half of...

Altera Infrastructure executes Restructuring Support Agreement with majority of secured lenders, enters Chapter 11 to strengthen capital structure and position for long-term growth

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Restructuring will be implemented through a pre-arranged Chapter 11 process in U.S. Bankruptcy Court Restructuring will significantly deleverage Altera’s balance sheet and facilitate a long term, sustainable positive liquidity outlook Brookfield Business Partners L.P., and certain of its affiliates and institutional partners (collectively, “Brookfield”) to equitise more than $750 million of debt upon consummation of the transactions and to provide an additional $50 million debtor in possession financing facility to help fund the Chapter 11 process Altera will continue to operate in the normal course during restructuring Altera Shuttle Tankers and FPSO J/Vs not part of restructuring processWESTHILL, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) — Altera Infrastructure L.P. and certain of its subsidiaries (“Altera”), one of the...

Gofore Plc: Gofore Plc’s Half-year Report for January-June 2022: Strategy execution continues to bring great results – net sales +40% and adjusted EBITA +54%

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Gofore Plc Half-year Report 15 August, 2022 AT 9 A.M. EET Inside information Gofore Plc’s Half-year Report for January-June 2022: Strategy execution continues to bring great results – net sales +40% and adjusted EBITA +54% January-June 2022Net sales grew by 40% to EUR 72.5 (51.7) million. Organic net sales growth accounted for well over half of total growth (25%). Adjusted EBITA grew by 54% to EUR 10.7 (6.9) million. Adjusted EBITA %, 14.8, improved from comparison period (13.4%). Number of employees grew by 34%, to a total of 1,074 (803) people. Net sales from private sector customers grew by 58 % and public sector customers sales by 31%. Raise in customer pricing was an average of 4.2% and salary raises on average 5.6% (both excl. Devecto), which means higher prices compensated for the impact of salary raises. Net sales generated...

Company announcement no 12/2022 – Interim Report Q2 2022 and summons to written resolutions

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Interim Report Q2 2022 and summons to written resolutions EBITDA fixed herd prices (FHP) for Q2 2022 decreased to 5,733 mEUR (Q2 2021: 6,111 kEUR), corresponding to an EBITDA margin FHP of 22.1% (Q2 2021: 21.6%). The quarterly EBITDA decreased by 378 kEUR (compared to Q2 2021), but the relatively small change has several significant effects. On the positive side, subsidy in LT of 2.530 kEUR and improved sales prices in LT of 3.104 kEUR, nevertheless increasing feed prices, lower sales prices in Russia, higher production cost combined with Ostrov site only partly in operation are higher than the positive effects. Sales prices in Q2 were 1.31 EUR/kg live weight, up from 1,20 EUR/kg (Q2 2021). Better prices have been driven by the price increase in LT, which increased by 0,24 EUR/kg compared to 2021. Feed prices in Q2 2022 were 282 EUR/T...

Maha Energy AB Announces Filing of Second Quarter 2022 Report & Live Webcast

Written by Customer Service on August 15, 2022. Posted in Earnings Releases And Operating Results.

Maha Energy AB (publ) (“Maha” or the “Company”) is pleased to announce its second quarter results. The report is attached to this press release and available on the Company’s website at www.mahaenergy.ca. Second Quarter 2022The Tie-5 well was completed free-flowing 766 BOEPD (590 BOPD and 1,054 MSCFPD) and is now producing through the Tie field’s permanent facilities. The Tie-6 well was spudded in June and can potentially be hooked up for production during Q3. Daily oil & gas production for Q2 2022 averaged 3,292 BOEPD (Q2 2021: 3,104 BOEPD) Revenue of USD 24.0 million (Q2 2021: USD 15.2 million) Operating netback of USD 17.4 million or USD 64.72 per BOE (Q2 2021: USD 9.5 million or USD 35.46 per BOE) EBITDA of USD 14.6 million (Q2 2021: USD 9.0 million) Net result of USD 8.2 million (Q2 2021: USD 2.6 million) Basic and Diluted...

Proactive news headlines including Silver Mines, Polymetals Resources, Creso Pharma and Core Lithium

Written by Customer Service on August 15, 2022. Posted in Mergers And Acquisitions.

Sydney, Aug. 15, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Silver Mines Ltd (ASX:SVL) says a recently-completed 2D seismic reflection survey has clearly defined the Bowdens silver deposit and its potential system extensions near Mudgee in New South Wales. Click here Polymetals Resources Ltd (ASX:POL) has discovered broad zones of higher-grade gold from phase three drilling, which reinforce the prospectivity of the Alahiné Gold Project in Guinea’s Siguiri Basin. Click here Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)’s Canadian subsidiary Creso Pharma ImpACTIVE Inc has appointed decorated multi-sport performance coach Kolby Tullier as a brand ambassador. Click here Core Lithium Ltd (ASX:CXO) has kicked off a reverse...

Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, 2022 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates has been extended until March 31, 2023. As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx. US $900,000) of additional research funding. The reserved indications, where Addex retains exclusive rights to develop its own independent...

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

Written by Customer Service on August 15, 2022. Posted in Public Companies.

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be presented at an upcoming medical meetingNovartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancerBasel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an...

Month: August 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals